Cisapride mini-tablet formulations
December 22, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesAnti-diarrheal anilino nicotinic acids and method of using same Method and composition for the preparation of controlled long-acting pharmaceuticals Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose Pharmaceutical multiple-units formulation Multimode perimeter intrusion detection system Sustained release compositions comprising hydroxypropyl cellulose ethers Taste concealing pharmaceutical dosage unit Drug delivery system Drug delivery system Sustained release pharmaceutical preparations having pH controlled membrane coatings InventorsAssigneeApplicationNo. 995583 filed on 12/22/1997US Classes:424/461, Containing polysaccharide (e.g., cellulose sugars, etc.)424/451, Capsules (e.g., of gelatin, of chocolate, etc.)424/457, Sustained or differential release424/458, Containing discrete coated particles pellets, granules, or beads424/459, Organic coatings424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/490, Coated (e.g., microcapsules)424/493, Containing polysaccharides (e.g., sugars)424/494Cellulose derivativesExaminersPrimary: Page, Thurman K.Assistant: Seidleck, Brian K. Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/62A61K 009/50 Foreign Application Priority Data1997-01-03 IEAbstractA sustained release cisapride oral dosage formulation suitable for once-daily administration comprises a plurality of mini-tablets containing cisapride or a salt thereof with an organic acid and capable of releasing cisapride at different sites along the gastrointestinal tract. The mini-tablets include a proportion of immediate release tablets and a proportion of tablets which release cisapride in response to the pH environment at a given site in the distal regions of the gastrointestinal tract and which include cisapride or a salt thereof embedded in a matrix of hydrophilic polymer, said matrix being coated with a pH dependent polymer, the formulation having a Cmax/Cmin ratio under steady state conditions of 2:1 or less as evidenced by a substantially flat plasma profile in vivo.Other References
Field of SearchCapsules (e.g., of gelatin, of chocolate, etc.)Gelatin Sustained or differential release Containing discrete coated particles pellets, granules, or beads Containing solid synthetic polymers Containing polysaccharide (e.g., cellulose sugars, etc.) Matrices Synthetic polymer Acrylic acid and derivatives Polysaccharides (e.g., cellulose, etc.) Coated (e.g., microcapsules) Containing polysaccharides (e.g., sugars) Cellulose derivatives Containing solid synthetic polymers | |
